Harrow (HROW) Preferred Dividend Payments (2012 - 2021)
Harrow's (HROW) quarterly Preferred Dividend Payments came in at $472000.0 in Q2 2021, up 136.0% quarter-over-quarter from $200000.0 in Q2 2012.
Harrow (HROW) Preferred Dividend Payments (2012 - 2021) Analysis & Trends
Harrow's Preferred Dividend Payments history runs 2 years deep, the most recent figure standing at $472000.0 for Q2 2021.
- On a quarterly basis, Preferred Dividend Payments changed N/A year-over-year to $472000.0 in Q2 2021; TTM through Dec 2021 was $472000.0, a N/A change from a year earlier, with the FY2021 full-year figure at $472000.0, changed N/A from the prior year.
- Preferred Dividend Payments rose to $472000.0 in Q2 2021 per HROW's latest filing, from $200000.0 in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $472000.0 in Q2 2021 and bottomed at $472000.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Harrow | 1.43 Bn | 1.34 Bn | 27.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 472,000.00 |
| Jun 30, 2012 | 200,000.00 |